Few prospective studies in cutaneous and systemic lupus erythematosus (CLE/SLE) assessed thalidomide-induced peripheral neuropathy (TiPN) incidence/reversibility, and most have not excluded confounding causes neither monitored thalidomide plasma levels.
Objectives
To evaluate TiPN incidence/reversibility, coasting effect and its association with thalidomide plasma levels in CLE/SLE.
Methods
One-year prospective study of thalidomide in 20 CLE/SLE patients without pregnancy potential, with normal nerve conduction study (NCS), and excluded other PN causes. Thalidomide levels were determined by high-performance liquid chromatography/tandem mass spectrometry.
Results
Twelve patients (60%) developed TiPN: 33.3% were symptomatic and 66.6% asymptomatic. Half of this latter group developed coasting effect (TiPN symptoms 1-3 months after drug withdrawal). The main predictive factors for TiPN were treatment duration ≥6 months (p = 0.025) and cumulative dose (p = 0.023). No difference in plasma thalidomide levels between patients with/without TiPN was observed (p = 0.464). After drug withdrawal, 75% symptomatic TiPN patients improved their symptoms. Seven TiPN patients underwent an additional NCS after drug withdrawal: 42.8% worsened NCS, 14.2% was stable, and 42.8% had improved NCS.
Conclusion
Our data provides novel evidence of coasting effect in half of asymptomatic patients with TiPN. The irreversible nature of this lesion in 25% of TiPN patients reinforces the relevance of early NCS monitoring, and suggests thalidomide use solely as a bridge for other effective therapy for refractory cutaneous lupus patients.
TebbeBOrfanosCE.Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus1997;
6: 96–104.
2.
VasquezRWangDTranQP, et al.
A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus. Br J Dermatol2013;
168: 145–153.
3.
KuhnAAbererEBata-CsörgőZ, et al.
S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European dermatology forum (EDF) in cooperation with the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol2017;
31: 389–404.
4.
FanouriakisAKostopoulouMAlunnoA, et al.
2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019;
78: 736–745.
5.
ChassetFTounsiTCesbronEBarbaudAFrancèsCArnaudL.Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol2018;
78: 342–350.
6.
Yuki EFN, Silva CA and Aikawa NE, et al. Thalidomide and lenalidomide for refractory systemic/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice. J Clin Rheumatol 2019; Epub ahead pf print, doi: 10.1097/RHU.0000000000001160.
7.
CuadradoMJKarimYSannaGSmithEKhamashtaMAHughesGRV.Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens. Am J Med2005;
118: 246–250.
8.
FrankelHCSharonVRVleugelsRAMerolaJFQureshiA.Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity. Int J Dermatol2013;
52: 1407–1409.
9.
ZaraGErmaniMRondinoneRArientiSDoriaA.Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry2008;
79: 1258–1261.
10.
Bastuji-GarinSOchoniskySBoucheP, et al.
Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol2002;
119: 1020–1026.
11.
HaimNEpelbaumRBen-ShaharMYarnitskyDSimriWRobinsonE.Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer1994;
73: 2515–2519.
12.
EldersonAGerritsen van der HoopRHaanstraWNeijtJPGispenWHJennekensFG.Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity. J Neurol Sci1989;
93: 167–174.
13.
FlemingFJVytopilMChaitowJJonesHRJrDarrasBTRyanMM.Thalidomide neuropathy in childhood. Neuromuscul Disord2005;
15: 172–176.
14.
JohannessenSILandmarkCJ.Value of therapeutic drug monitoring in epilepsy. Expert Rev Neurother2008;
8: 929–939.
15.
DwivediRSinghMKaleekalTGuptaYKTripathiM.Concentration of antiepileptic drugs in persons with epilepsy: a comparative study in serum and saliva. Int J Neurosci2015;
6: 1–7.
16.
Costedoat-ChalumeauNAmouraZHulotJ-S, et al.
Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum2006;
54: 3284–3290.
17.
PedrosaTNPasotoSGAikawaNE, et al.
Understanding the dynamics of hydroxychloroquine blood levels in lupus nephritis. Lupus2020;
29: 560–568.
18.
FrancèsCCosnesADuhautP, et al.
Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol2012;
148: 479–484.
KakimotoTHattoriYOkamotoS, et al.
Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res2002;
93: 1029–1036.
21.
KodamaTAbeMIidaS, et al.
A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. Clin Lymphoma Myeloma2009;
9: 154–159.
22.
AckermanAB.Histologic diagnosis of inflammatory skin diseases: a method by pattern analysis.
Philadelphia:
Lea & Febiger, 1978, p.813.
23.
HochbergMC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725.
24.
HarrisPATaylorRThielkeRPayneJGonzalezNCondeJG.Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform2009;
42: 377–381.
Zeldis JB, Williams BA, Thomas SD, Elsayed ME. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 1999; 21: 319–330.
AlbrechtJTaylorLBerlinJA, et al.
The CLASI (cutaneous lupus erythematosus disease area and severity index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol2005;
125: 889–894.
30.
BouhassiraDAttalNAlchaarH, et al.
Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain2005;
114: 29–36.
31.
DelgadoALimaM.Contributo Para a validação concorrente de uma medida de adesão aos tratamentos. Psic Saúde Doenças2001;
2: 81–100.
32.
Oliveira-SantosMVeraniJFCamachoLAde AndradeCAFerrante-SilvaRKlumbEM.Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio De Janeiro, Brazil: study protocol for a randomized controlled trial. Trials2016;
17: 181.
33.
Cortés-HernándezJTorres-SalidoMCastro-MarreroJVilardell-TarresMOrdi-RosJ.Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol2012;
166: 616–623.
34.
CoelhoASoutoMICardosoCR, et al.
Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients. Lupus2005;
14: 434–439.
ChenSAndaryMBuschbacherR, et al.
Electrodiagnostic reference values for upper and lower limb nerve conduction studies in adult populations. Muscle Nerve2016;
54: 371–377.
37.
LaguenyARommelAVignollyB, et al.
Thalidomide neuropathy: an electrophysiologic study. Muscle Nerve1986;
9: 837–844.
38.
Gardner-MedwinJMSmithNJPowellRJ.Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet’s disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis1994;
53: 828–832.
39.
ErikssonTBjörkmanSFygeAEkbergH.Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr1992;
582: 211–216.
40.
CLSI. Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. CLSI document EP06-A, Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, 2003.
41.
CLSI. Protocols for determination of limits of detection and limits of quantitation; approved guideline. CLSI document EP17-A, Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, 2004.
42.
CLSI. Mass spectrometry in the clinical laboratory: general principles and guidance; approved guideline. CLSI document C50-A, Clinical and Laboratory Standards Institute, Wayne, Pennsylvania, 2007.
43.
Associação Brasileira de Empresas de Pesquisa. Critério Brasil 2015 e atualização da distribuição de classes para 2016, www.abep.org/criterio-brasil. (2013, accessed 6 June 2020).
44.
GladmanDGinzlerEGoldsmithC, et al.
The development and initial validation of the systemic lupus international collaborating clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum1996;
39: 363–369.
45.
Ordi-RosJCortésFCucurullEMauriMBujánSVilardellM.Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol2000;
27: 1429–1433.
46.
TesfayeSVileikyteLRaymanG, et al.
Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev2011;
27: 629–638.
47.
FouargeEMaquetP.Conséquences neurologiques centrales et périphériques de l’alcoolisme (neurological consequences of alcoholism). Rev Med Liege2019;
74: 310–313.
48.
WulffCHHøyerHAsboe-HansenGBrodthagenH.Development of polyneuropathy during thalidomide therapy. Br J Dermatol1985;
112: 475–480.
49.
BrianiCZaraGRondinoneR, et al.
Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus. Neurology2004;
62: 2288–2290.
50.
WalchnerMMeurerMPlewigGMesserG.Clinical and immunologic parameters during thalidomide treatment of lupus erythematosus. Int J Dermatol2000;
39: 383–388.
51.
CavalettiGBeronioAReniL, et al.
Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology2004;
62: 2291–2293.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
